CSL Limited (ASX:CSL – Get Free Report) insider Megan Clark bought 132 shares of the stock in a transaction that occurred on Wednesday, February 19th. The shares were purchased at an average price of A$264.85 ($168.69) per share, with a total value of A$34,959.94 ($22,267.48).
CSL Stock Performance
The company has a current ratio of 1.86, a quick ratio of 1.68 and a debt-to-equity ratio of 64.46. The stock has a market capitalization of $77.43 billion, a PE ratio of 28.02, a PEG ratio of 1.29 and a beta of 0.32.
CSL Increases Dividend
The firm also recently announced a Interim dividend, which will be paid on Tuesday, April 8th. Shareholders of record on Tuesday, April 8th will be issued a dividend of $2.073 per share. The ex-dividend date of this dividend is Sunday, March 9th. This is a positive change from CSL’s previous Interim dividend of $1.83. This represents a yield of 0.81%. CSL’s dividend payout ratio is 50.38%.
CSL Company Profile
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.
Read More
- Five stocks we like better than CSL
- Growth Stocks: What They Are, What They Are Not
- 3 Stocks Poised to Thrive as NVIDIA Dominates the AI Boom
- 3 Small Caps With Big Return Potential
- MercadoLibre: High-Growth EM Stock With 100% Upside Potential
- Differences Between Momentum Investing and Long Term Investing
- As the Magnificent 7 Stalls, These 3 Stocks Are Gaining Momentum
Receive News & Ratings for CSL Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CSL and related companies with MarketBeat.com's FREE daily email newsletter.
